Marksans Pharma Ltd. Fundamental & Technical Research, Share Price Today

NSE : MARKSANS
NIFTY : Nifty Microcap 250

About Company

Marksans Pharma is an Indian pharmaceutical company having a global footprint. Their strengths lie in research, manufacturing and marketing of finished dosage pharmaceutical formulations. The company’s R&D capabilities include dossier development, chemical synthesis, process optimization, formulation development, analytical development and conducting stability studies. Its key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others. The company manufacture a wide range of solid oral dosage in the form of Tablets (plain, enteric coated and film coated), Hard Gelatin Capsule and Soft Gelatin Capsules.

Market Cap. ₹8,824 Cr.

52 Week - High/Low ₹359/130

P/E Ratio 48.08

P/B Ratio 7.22

Enterprise Value ₹8,536 Cr.

ROE % 11.46

RSI Value 37.47

EMA 50 228.58

EMA 200 237.53

Net Profit 134 Cr.

Net Profit 3year growth 35.96 Cr.

Net Profit 3 year (back) 98 Cr.

Debt to Equity 0.0 %

EPS Growth TTM 52.26 %

Current Ratio 3.22 %

100 Day SMA 264 Rs.

200 Day SMA 252 Rs.

21 Day SMA 212 Rs.

50 Day SMA 226 Rs.

Book Value 27 Rs.

EV/EBITDA Ratio 33

QoQ EPS Growth -12 %

QoQ Operating Profit Growth 15 %

QoQ Sales Growth 1 %

Sales Latest Quarter 312 Cr.

YoY Sales Growth 29 %

Market Cap. ₹8,824 Cr.

52 Week - High/Low ₹359/130

P/E Ratio 23.95

P/B Ratio 4.27

Enterprise Value ₹8,359 Cr.

ROE % 16.53

RSI Value 37.47

EMA 50 228.58

EMA 200 237.53

Net Profit 314 Cr.

Net Profit 3year growth 5.61 Cr.

Net Profit 3 year (back) 236 Cr.

Debt to Equity 0.01 %

EPS Growth TTM 13.39 %

Current Ratio 4.78 %

100 Day SMA 264 Rs.

200 Day SMA 252 Rs.

21 Day SMA 212 Rs.

50 Day SMA 226 Rs.

Book Value 46 Rs.

EV/EBITDA Ratio 14

QoQ EPS Growth 8 %

QoQ Operating Profit Growth 2 %

QoQ Sales Growth 6 %

Sales Latest Quarter 682 Cr.

YoY Sales Growth 16 %

Add Parameters

Valuation

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages